These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 37047505)
1. Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway. Al-Qabbaa SM; Qaboli SI; Alshammari TK; Alamin MA; Alrajeh HM; Almuthnabi LA; Alotaibi RR; Alonazi AS; Bin Dayel AF; Alrasheed NM; Alrasheed NM Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047505 [TBL] [Abstract][Full Text] [Related]
2. Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats. Al-Rasheed NM; Al-Rasheed NM; Hasan IH; Al-Amin MA; Al-Ajmi HN; Mahmoud AM Drug Des Devel Ther; 2016; 10():2095-107. PubMed ID: 27418808 [TBL] [Abstract][Full Text] [Related]
3. The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes. Marques C; Gonçalves A; Pereira PMR; Almeida D; Martins B; Fontes-Ribeiro C; Reis F; Fernandes R Life Sci; 2019 Oct; 234():116738. PubMed ID: 31398418 [TBL] [Abstract][Full Text] [Related]
4. Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway. Wang D; Zhang G; Chen X; Wei T; Liu C; Chen C; Gong Y; Wei Q Int J Mol Med; 2018 May; 41(5):2784-2792. PubMed ID: 29484381 [TBL] [Abstract][Full Text] [Related]
5. The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice Li L; Lian X; Wang Z; Zheng J; Liu J; Chu Y; Teng Y; Zhang Z Pharmazie; 2019 Apr; 74(4):239-242. PubMed ID: 30940309 [TBL] [Abstract][Full Text] [Related]
6. Sitagliptin's renoprotective effect in a diabetic nephropathy model in rats: The potential role of PI3K/AKT pathway. Mohamed RH; Sedky AA; Hamam GG; Elkhateb L; Kamar SA; Adel S; Tawfik SS Fundam Clin Pharmacol; 2022 Apr; 36(2):324-337. PubMed ID: 34735026 [TBL] [Abstract][Full Text] [Related]
7. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways. Ibrahim SSA; Salama MA; Selima E; Shehata RR Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539 [TBL] [Abstract][Full Text] [Related]
8. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats. Liu YS; Huang ZW; Wang L; Liu XX; Wang YM; Zhang Y; Zhang M J Pharmacol Sci; 2015 Mar; 127(3):260-74. PubMed ID: 25837922 [TBL] [Abstract][Full Text] [Related]
9. Effect of siglidine on glucose lipid metabolism and the expression of iNOS and GLP-1 receptors in diabetic rats. Zhang HY; Li Y; Zhong YH; Ruan LB; Yang TR; Yin HP Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8984-8989. PubMed ID: 30575943 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats. Karabulut S; Coskun ZM; Bolkent S Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375 [TBL] [Abstract][Full Text] [Related]
11. Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy. Ren X; Liu G; Wang Y; Zhang W; Xue F; Li R; Yu W Pharmacology; 2017; 100(1-2):1-13. PubMed ID: 28329747 [TBL] [Abstract][Full Text] [Related]
14. Role of the integrin-linked kinase/TGF-β/SMAD pathway in sitagliptin-mediated cardioprotective effects in a rat model of diabetic cardiomyopathy. Bin Dayel AF; Alonazi AS; Alrasheed NM; Alamin MA; Sarawi WS; Alharbi AO; Alabbad NA; Albuaijan DA; Alassiri DN; Aljarbua AF; Almusaytir FK; Alrasheed NM J Pharm Pharmacol; 2024 Jan; 76(1):64-73. PubMed ID: 37992247 [TBL] [Abstract][Full Text] [Related]
15. Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats. Eitah HE; Maklad YA; Abdelkader NF; Gamal El Din AA; Badawi MA; Kenawy SA Toxicol Appl Pharmacol; 2019 Feb; 365():30-40. PubMed ID: 30576699 [TBL] [Abstract][Full Text] [Related]
16. Sitagliptin ameliorates diabetic nephropathy by upregulating renal nephrin and podocin expression through modulation of adipokines levels. Ashraf A; Akhtar T; Shabbir A; Aftab U; Shahzad M Fundam Clin Pharmacol; 2023 Jun; 37(3):549-555. PubMed ID: 36594370 [TBL] [Abstract][Full Text] [Related]
17. Effects of sitagliptin on ß-adrenoceptor mediated relaxation in streptozotocin-diabetic rat aorta. Müderrisoğlu AE; Erdoğan BR; Yeşilyurt ZE; Uyar Boztaş C; Karaçömerlioğlu İ; Altan VM; Arıoğlu İnan E Turk J Med Sci; 2021 Apr; 51(2):864-872. PubMed ID: 33185366 [TBL] [Abstract][Full Text] [Related]
18. Role of the JAK/STAT pathway in a streptozotocin-induced diabetic retinopathy mouse model. Cho CH; Roh KH; Lim NY; Park SJ; Park S; Kim HW Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3553-3563. PubMed ID: 35599279 [TBL] [Abstract][Full Text] [Related]
19. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase. Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Interleukin-23 and Rezaeepoor M; Hoseini-Aghdam M; Sheikh V; Eftekharian MM; Behzad M J Interferon Cytokine Res; 2020 Nov; 40(11):515-523. PubMed ID: 33136467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]